

Dear Editor,

We submit a revised version of our invited editorial titled "Considerations for the management of patients with diabetes mellitus and acute COVID-19", manuscript ID 76779, for consideration for publication in the World Journal of Diabetes. We thank the Reviewers for their comments, which improved our paper. We modified the text accordingly. All changes are shown in red in the revised manuscript.

Response to Reviewers' comments

**Reviewer's code:** 05866045

Please write the limitation of the study.

**We added in the Conclusions "There are currently limited data regarding the safety and efficacy of both antidiabetic and antiviral treatments in diabetic patients with acute COVID-19."**

**Reviewer's code:** 06179533

1.Title: Appropriate. 2.Abstract: Appropriate. 3.Key words: Appropriate. 4.Background: Appropriate. 5.Methods: N/A 6. Results: N/A 7.Discussion: Generally the manuscript offers valuable information about the management of DM in COVID-19 patients. I have some recommendations:- The general information about insulin and its dosing regimen are too detailed, it should be summarized and the author should concentrate on the dose adjustments related with COVID-19.- Both DM and COVID 19 cause microangiopathy,

and co-occurrence of the both disease increases the possibility of complications. The need for anticoagulant and antiaggregant agents can be increased. These situations should be explained. 8.Illustrations and tables: N/A 9.Biostatistics: N/A 10.Units: Appropriate. 11.References: Appropriate. 12.Quality of manuscript organization and presentation: Appropriate. 13. Research methods and reporting: Appropriate. 14.Ethics statements: N/A

We thank this Reviewer for stating “Generally the manuscript offers valuable information about the management of DM in COVID-19 patients.” We summarized the section on insulin and its dosing regimen. We now focus more on the dose adjustments related with COVID-19. We also added a section on the increased risk for thrombosis in these patients and the role of antithrombotic treatment (page 8) where we mention “Notably, patients with acute COVID-19 are at higher risk for thrombosis than the general inpatient population and the presence of DM further increases this risk. Accordingly, this population should be carefully monitored for the occurrence of thrombotic events and should receive prophylactic dose of heparin. In patients who are already receiving antiplatelet agents for DM or for established cardiovascular disease, these should be continued and low-dose heparin should be added.”

**Reviewer's code:** 06082616

There is a lot of useful information in the article. The reader will understand the issues involved in diabetes and COVID-19 infection better if there is more organization to the manuscript. I suggest the following subheadings: 1. Incidence and risk factors for COVID-19 in pre-existing DM, including ICU admission 2. Prognostic factors after COVID-19 infection develops, including specific comorbidities (for example, organ transplants, heart disease) 3.

Hyperglycemia management, including how to use insulin especially if new-onset diabetes 4. Long-COVID and suggestions for future research.

**We thank this Reviewer for stating “There is a lot of useful information in the article.” We added these subheadings in the revised text.**

**Reviewer’s code: 05426937**

This manuscript is a little messy on the whole. It is suggested to divide it into several parts and rewrite each part with a subtitle.

**We divided the manuscript into several parts and we rewrote each part with a subtitle.**

Yours sincerely,

Konstantinos Tziomalos, MD, PhD

Assistant Professor of Internal Medicine

Medical School, Aristotle University of Thessaloniki, Greece